Summit Therapeutics Inc. (SMMT)

Market Cap	3.15B
Revenue (ttm)	n/a
Net Income (ttm)	-116.03M
Shares Out	701.97M
EPS (ttm)	-0.00
PE Ratio	12.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,836,185
Open	4.810
Previous Close	4.685
Day's Range	4.410 - 4.890
52-Week Range	1.500 - 5.390
Beta	-1.13
Analysts	Strong Buy
Price Target	7.50 (+67.04%)
Earnings Date	May 1, 2024

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: SMMT

Financial Performance

Financial numbers in GBP

Analyst Forecast

According to 2 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 67.04% from the latest price.

Price Target

$7.5

(67.04% upside)

Analyst Consensus: Strong Buy